» Articles » PMID: 15708435

Neocortical Synaptic Bouton Number is Maintained Despite Robust Amyloid Deposition in APP23 Transgenic Mice

Overview
Journal Neurobiol Aging
Publisher Elsevier
Date 2005 Feb 15
PMID 15708435
Citations 31
Authors
Affiliations
Soon will be listed here.
Abstract

Major pathological findings in Alzheimer's disease (AD) brain include the deposition of amyloid-beta and synapse loss. Synaptic loss has been shown to correlate with the cognitive decline in AD patients, but the relationship between cerebral amyloidosis and synapse loss is complicated by the presence of neurofibrillary tangles and other lesions in AD brain. With the use of the APP23 transgenic mouse model that overexpresses human amyloid precursor protein (APP) with the Swedish double mutation, we investigated whether the development of cortical amyloid deposition was accompanied by synaptic bouton loss. With stereological methods, we show that despite robust age-related cortical amyloid deposition with associated synaptic degeneration, the total number of cortical synaptophysin-positive presynaptic terminals is not changed in 24-month-old animals compared with 3-, 8-, and 15-month-old APP23 mice. Wild-type mice also do not show an age-related loss of presynaptic boutons in the neocortex and are not significantly different from APP23 mice. Synaptophysin Western blotting revealed no significant difference between APP23 mice and wild-type controls at 3 and 25 months of age. Our results suggest that cerebral amyloidosis is not sufficient to account for the global synapse loss in AD. Alternatively, a putative trophic effect of APP may prevent, compensate, or delay a loss of synapses in this mouse model.

Citing Articles

Navigating Alzheimer's Disease Mouse Models: Age-Related Pathology and Cognitive Deficits.

De Plano L, Saitta A, Oddo S, Caccamo A Biomolecules. 2024; 14(11).

PMID: 39595581 PMC: 11592094. DOI: 10.3390/biom14111405.


Repeated exposure to novelty promotes resilience against the amyloid-beta effect through dopaminergic stimulation.

Velazquez-Delgado C, Hernandez-Ortiz E, Landa-Navarro L, Tapia-Rodriguez M, Moreno-Castilla P, Bermudez-Rattoni F Psychopharmacology (Berl). 2024; 242(1):85-100.

PMID: 39145803 PMC: 11742894. DOI: 10.1007/s00213-024-06650-5.


Cerebrovascular Dysfunction in Alzheimer's Disease and Transgenic Rodent Models.

Fang X, Fan F, Border J, Roman R J Exp Neurol. 2024; 5(2):42-64.

PMID: 38434588 PMC: 10906803. DOI: 10.33696/neurol.5.087.


Critical thinking of Alzheimer's transgenic mouse model: current research and future perspective.

Li X, Quan M, Wei Y, Wang W, Xu L, Wang Q Sci China Life Sci. 2023; 66(12):2711-2754.

PMID: 37480469 DOI: 10.1007/s11427-022-2357-x.


Tyrosine phosphatase STEP in human dementia and in animal models with amyloid and tau pathology.

Taylor D, Kneynsberg A, van Roijen M, Gotz J Mol Brain. 2023; 16(1):6.

PMID: 36639708 PMC: 9840288. DOI: 10.1186/s13041-023-00994-3.